Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes
- Status
- TERMINATED
- Phase
- PHASE1
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE2
Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
- Status
- TERMINATED
- Phase
- PHASE2
Study of INCB053914 in Subjects With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
- Status
- COMPLETED
- Phase
- PHASE3
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- PHASE1
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE1
Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT
- Status
- COMPLETED
- Phase
- PHASE2
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.
- Status
- COMPLETED
- Phase
- PHASE2